Compounds > gr 113808
Page last updated: 2024-09-03

gr 113808 and Parkinsonian Disorders

gr 113808 has been researched along with Parkinsonian Disorders in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Du, CX; Guo, Y; Liu, J; Lv, SX; Wang, HS; Wang, T; Xie, W; Zhang, J; Zhang, L1
De Deurwaerdère, P; Di Giovanni, G; Navailles, S1

Other Studies

2 other study(ies) available for gr 113808 and Parkinsonian Disorders

ArticleYear
Activation and blockade of serotonin
    Neurological research, 2019, Volume: 41, Issue:7

    Topics: Animals; Benzimidazoles; Brain; Bridged Bicyclo Compounds, Heterocyclic; Dopamine; Dose-Response Relationship, Drug; Habenula; Indoles; Male; Maze Learning; Memory, Short-Term; Microinjections; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Agonists; Serotonin 5-HT4 Receptor Antagonists; Substantia Nigra; Sulfonamides

2019
The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:9

    Topics: Animals; Benzofurans; Brain; Dopamine; Dopamine Agents; Functional Laterality; Indoles; Levodopa; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin 5-HT4 Receptor Agonists; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides

2015